Cargando…
Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
BACKGROUND: Renal renin-angiotensin system (RAS) activation is one of the important pathogenic mechanisms in the development of diabetic nephropathy in type 2 diabetes. The aim of this study was to investigate the effects of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, dapagliflozin, on ren...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089752/ https://www.ncbi.nlm.nih.gov/pubmed/27802313 http://dx.doi.org/10.1371/journal.pone.0165703 |
_version_ | 1782464294167773184 |
---|---|
author | Shin, Seok Joon Chung, Sungjin Kim, Soo Jung Lee, Eun-Mi Yoo, Young-Hye Kim, Ji-Won Ahn, Yu-Bae Kim, Eun-Sook Moon, Sung-Dae Kim, Myung-Jun Ko, Seung-Hyun |
author_facet | Shin, Seok Joon Chung, Sungjin Kim, Soo Jung Lee, Eun-Mi Yoo, Young-Hye Kim, Ji-Won Ahn, Yu-Bae Kim, Eun-Sook Moon, Sung-Dae Kim, Myung-Jun Ko, Seung-Hyun |
author_sort | Shin, Seok Joon |
collection | PubMed |
description | BACKGROUND: Renal renin-angiotensin system (RAS) activation is one of the important pathogenic mechanisms in the development of diabetic nephropathy in type 2 diabetes. The aim of this study was to investigate the effects of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, dapagliflozin, on renal RAS in an animal model with type 2 diabetes. METHODS: Dapagliflozin (1.0 mg/kg, OL-DA) or voglibose (0.6 mg/kg, OL-VO, diabetic control) (n = 10 each) was administered to Otsuka Long-Evans Tokushima Fatty (OLETF) rats for 12 weeks. We used voglibose, an alpha-glucosidase inhibitor, as a comparable counterpart to SGLT2 inhibitor because of its postprandial glucose-lowering effect without proven renoprotective effects. Control Long-Evans Tokushima Otsuka (LT) and OLETF (OL-C) rats received saline (n = 10, each). Changes in blood glucose, urine albumin, creatinine clearance, and oxidative stress were measured. Inflammatory cell infiltration, mesangial widening, and interstitial fibrosis in the kidney were evaluated by histological analysis. The effects of dapagliflozin on renal expression of the RAS components were evaluated by quantitative RT-PCR in renal tissue. RESULTS: After treatment, hyperglycemia and urine microalbumin levels were attenuated in both OL-DA and OL-VO rather than in the OL-C group (P < 0.05). The urine angiotensin II (Ang II) and angiotensinogen levels were significantly decreased following treatment with dapagliflozin or voglibose, but suppression of urine Ang II level was more prominent in the OL-DA than the OL-VO group (P < 0.05). The expressions of angiotensin type 1 receptor and tissue oxidative stress markers were markedly increased in OL-C rats, which were reversed by dapagliflozin or voglibose (P < 0.05, both). Inflammatory cell infiltration, mesangial widening, interstitial fibrosis, and total collagen content were significantly increased in OL-C rats, which were attenuated in OL-DA group (P < 0.05). CONCLUSION: Dapagliflozin treatment showed beneficial effects on diabetic nephropathy, which might be via suppression of renal RAS component expression, oxidative stress and interstitial fibrosis in OLETF rats. We suggest that, in addition to control of hyperglycemia, partial suppression of renal RAS with an SGLT2 inhibitor would be a promising strategy for the prevention of treatment of diabetic nephropathy. |
format | Online Article Text |
id | pubmed-5089752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-50897522016-11-15 Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes Shin, Seok Joon Chung, Sungjin Kim, Soo Jung Lee, Eun-Mi Yoo, Young-Hye Kim, Ji-Won Ahn, Yu-Bae Kim, Eun-Sook Moon, Sung-Dae Kim, Myung-Jun Ko, Seung-Hyun PLoS One Research Article BACKGROUND: Renal renin-angiotensin system (RAS) activation is one of the important pathogenic mechanisms in the development of diabetic nephropathy in type 2 diabetes. The aim of this study was to investigate the effects of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, dapagliflozin, on renal RAS in an animal model with type 2 diabetes. METHODS: Dapagliflozin (1.0 mg/kg, OL-DA) or voglibose (0.6 mg/kg, OL-VO, diabetic control) (n = 10 each) was administered to Otsuka Long-Evans Tokushima Fatty (OLETF) rats for 12 weeks. We used voglibose, an alpha-glucosidase inhibitor, as a comparable counterpart to SGLT2 inhibitor because of its postprandial glucose-lowering effect without proven renoprotective effects. Control Long-Evans Tokushima Otsuka (LT) and OLETF (OL-C) rats received saline (n = 10, each). Changes in blood glucose, urine albumin, creatinine clearance, and oxidative stress were measured. Inflammatory cell infiltration, mesangial widening, and interstitial fibrosis in the kidney were evaluated by histological analysis. The effects of dapagliflozin on renal expression of the RAS components were evaluated by quantitative RT-PCR in renal tissue. RESULTS: After treatment, hyperglycemia and urine microalbumin levels were attenuated in both OL-DA and OL-VO rather than in the OL-C group (P < 0.05). The urine angiotensin II (Ang II) and angiotensinogen levels were significantly decreased following treatment with dapagliflozin or voglibose, but suppression of urine Ang II level was more prominent in the OL-DA than the OL-VO group (P < 0.05). The expressions of angiotensin type 1 receptor and tissue oxidative stress markers were markedly increased in OL-C rats, which were reversed by dapagliflozin or voglibose (P < 0.05, both). Inflammatory cell infiltration, mesangial widening, interstitial fibrosis, and total collagen content were significantly increased in OL-C rats, which were attenuated in OL-DA group (P < 0.05). CONCLUSION: Dapagliflozin treatment showed beneficial effects on diabetic nephropathy, which might be via suppression of renal RAS component expression, oxidative stress and interstitial fibrosis in OLETF rats. We suggest that, in addition to control of hyperglycemia, partial suppression of renal RAS with an SGLT2 inhibitor would be a promising strategy for the prevention of treatment of diabetic nephropathy. Public Library of Science 2016-11-01 /pmc/articles/PMC5089752/ /pubmed/27802313 http://dx.doi.org/10.1371/journal.pone.0165703 Text en © 2016 Shin et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Shin, Seok Joon Chung, Sungjin Kim, Soo Jung Lee, Eun-Mi Yoo, Young-Hye Kim, Ji-Won Ahn, Yu-Bae Kim, Eun-Sook Moon, Sung-Dae Kim, Myung-Jun Ko, Seung-Hyun Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes |
title | Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes |
title_full | Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes |
title_fullStr | Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes |
title_full_unstemmed | Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes |
title_short | Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes |
title_sort | effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089752/ https://www.ncbi.nlm.nih.gov/pubmed/27802313 http://dx.doi.org/10.1371/journal.pone.0165703 |
work_keys_str_mv | AT shinseokjoon effectofsodiumglucosecotransporter2inhibitordapagliflozinonrenalreninangiotensinsysteminananimalmodeloftype2diabetes AT chungsungjin effectofsodiumglucosecotransporter2inhibitordapagliflozinonrenalreninangiotensinsysteminananimalmodeloftype2diabetes AT kimsoojung effectofsodiumglucosecotransporter2inhibitordapagliflozinonrenalreninangiotensinsysteminananimalmodeloftype2diabetes AT leeeunmi effectofsodiumglucosecotransporter2inhibitordapagliflozinonrenalreninangiotensinsysteminananimalmodeloftype2diabetes AT yooyounghye effectofsodiumglucosecotransporter2inhibitordapagliflozinonrenalreninangiotensinsysteminananimalmodeloftype2diabetes AT kimjiwon effectofsodiumglucosecotransporter2inhibitordapagliflozinonrenalreninangiotensinsysteminananimalmodeloftype2diabetes AT ahnyubae effectofsodiumglucosecotransporter2inhibitordapagliflozinonrenalreninangiotensinsysteminananimalmodeloftype2diabetes AT kimeunsook effectofsodiumglucosecotransporter2inhibitordapagliflozinonrenalreninangiotensinsysteminananimalmodeloftype2diabetes AT moonsungdae effectofsodiumglucosecotransporter2inhibitordapagliflozinonrenalreninangiotensinsysteminananimalmodeloftype2diabetes AT kimmyungjun effectofsodiumglucosecotransporter2inhibitordapagliflozinonrenalreninangiotensinsysteminananimalmodeloftype2diabetes AT koseunghyun effectofsodiumglucosecotransporter2inhibitordapagliflozinonrenalreninangiotensinsysteminananimalmodeloftype2diabetes |